In order to further promote the innovation and development of domestic peptide industry, build an integrated communication and development platform for peptide basic research, drug research and development, industrial production and clinical application, and build a bridge for cooperation and mutual assistance between researchers and enterprises, on March 22, the preparatory meeting of peptide branch of China biochemical pharmaceutical industry association was successfully held at the headquarters of Beijing People's peptide group 。

More than 30 experts and scholars from the government, enterprise, academic and research circles gathered at guopeptide and launched a field discussion with harmonious atmosphere and outstanding achievements, which laid a solid foundation for the timely listing of peptide branch.

As the first association established specifically for peptide industry in China, peptide branch of China biochemical pharmaceutical industry association has received strong support from many association leaders and industry experts.

Liu Keliang, researcher of Institute of toxicants and drugs, Academy of military medicine, is to recommend Professor Li Yanmei, the first president of polypeptide branch, Professor Li Yanmei, Tsinghua University, Hu Wenyan, executive vice president and secretary-general of China biochemical pharmaceutical industry association, fan Huihong, director of China food and Drug Control Research Institute, Professor Luo Shizhong, School of life and technology, Beijing University of chemical technology and many other industry leaders to attend the meeting It was presided over by Meng Qingbin, deputy researcher of Institute of toxicants and drugs, Academy of military medicine.

As one of the initiators of peptide branch, Mr. Li Jianqi, chairman of the people's state peptide group, attended the meeting with a number of senior executives, and put forward a number of specific suggestions on the future development plan of peptide branch, industrialization of scientific research projects, cooperation between industry, University and research, which were unanimously recognized by the participants.

Liu Keliang, researcher of Institute of toxicants and drugs, Academy of military medicine (left center), the first president of peptide society to be recommended, Professor Li Yanmei, Tsinghua University (right center), Hu Wenyan, executive vice president and Secretary General of China Biochemical Pharmaceutical Industry Association (left bottom), and Meng Qingbin, deputy researcher of Institute of toxicants and drugs, Academy of military medicine (right bottom)

Meng Qingbin, deputy researcher, pointed out on the necessity of establishing the first polypeptide branch in China that, from a global perspective, currently Europe, the United States, Japan, Australia and even South Korea have their own polypeptide associations, while China has not yet had a relevant association on polypeptide industry, which does not match the current rapid development trend of peptide industry in China.

Take the development of peptide drugs as an example. In the past 20 years, more than 80 peptide drugs have been listed in the United States or Europe, and more than 150 peptide drugs are actively carrying out clinical research. It is estimated that the market size of peptide drugs will exceed 70 billion US dollars in 2019. At present, there are only 20 kinds of peptide drugs on the market in China, which are not only single in variety, but also more dependent on import. With the increasing attention of the industry and market demand, peptide drugs will have a huge development space in China in the future.

Speech by Chairman Li Jianqi

At the meeting, chairman Li Jianqi expressed his views on the spot from the perspective of the enterprise. He pointed out that the establishment of polypeptide branch is of great guiding significance for the development of the whole peptide industry in China. As an early high-tech enterprise engaged in bioactive peptide industry in China, the people's peptide group has made good market feedback from the early peptide nutrition food market,It began to gradually transform and upgrade to the research and development of food for special medical purposes and peptide drugs. Especially in peptide drug research and development, after years of intensive work in peptide industry, the people's peptide group has not only built a very mature whole industry development chain, but also accumulated a large number of user data, with unparalleled first mover advantage in the industry.

Joint peptide biomedical testing center of the people's Republic of China

In fact, in the research and development of peptide drugs, the people's peptide group has already begun to plan the layout. In 2018, the people's Government peptide group officially took the lead in establishing peptide protein drug development business division in the industry, which has three centers, namely peptide protein drug R & D center, biomedical information center, traditional Chinese medicine modernization development center, and more than 10 service departments, including academician workstation, peptide medicine joint test center, peptide industry information center, integrating production, education, research and investment, Covering the whole industrial chain from scientific research to pilot production, the company is committed to providing multi-level technical R & D support and services for peptide protein drug development projects in the mode of shared R & D platform, so as to meet the group's multi pipeline drug R & D and commercialization needs.

Site of preparatory meeting

The preparatory meeting also discussed the future development planning, organizational structure, management regulations and articles of association of polypeptide branch. The meeting decided to hold the inaugural meeting of polypeptide branch of China biochemical pharmaceutical industry association and the first China polypeptide Industry Forum in May 2019 in Hangzhou. At that time, the forum will invite hundreds of renowned experts and scholars in peptide industry at home and abroad, leaders of government departments and representatives of the business community,We will jointly make suggestions and suggestions on how to promote the scientific and healthy development of Chinese peptide industry, and strive to build a higher level of industry university research exchange and integration platform, so as to achieve precise docking between scientific research academic achievements and industrial projects, and quickly realize the transformation and landing of scientific and technological achievements.

Chairman Li Jianqi and Professor Li Yanmei discuss further in-depth cooperation and exchange

At present, there are many new problems and contradictions in the development of small and medium-sized enterprises, which are inevitable in the process of transformation and upgrading. Hong Huimin, member of the National Committee of the Chinese people's Political Consultative Conference, pointed out in his article "let industry associations come to the front desk" published in the people's Daily that the difficulty of upgrading and transformation of enterprises at this stage is that it is very difficult for the government to really understand the real development situation and needs of enterprises, and it is also difficult to accurately grasp the changes in the market. It is customary to use the administrative way of "laymen guide laymen", which wastes administrative resources and may break through Bad development environment for fair competition of enterprises.

The industry association is the organization of the peer enterprises, which can deeply and acutely perceive the existence, problems, potential dangers and development prospects of the industry. It is very familiar with the management level, technical reserves and core competitiveness level of different enterprises in the industry, and can effectively help enterprises realize transformation and upgrading in adversity. It is believed that the establishment of the peptide branch (cbpla-ps) will surely boost the development of China's bioactive peptide industry.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.